0002114044
Company
Hemab Therapeutics Holdings, Inc.
Biological Products, (No Diagnostic Substances) · COAG
ipo
amended
Nasdaq Global Select Market
S-1
Filing Timeline
SEC EDGAR
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common Stock · Exchange Nasdaq Global Select Market · Ticker COAG · Underwriters Goldman Sachs & Co. LLC, Jefferies, Evercore ISI
2026-04-10 · 0001193125-26-151378
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
2026-04-02 · 0001193125-26-140464
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Hemab Therapeutics Holdings, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its late-stage biotechnology pipeline focused on blood coagulation disorders. The company is developing two lead assets, sutacimig (HMB-001) and HMB-002, in clinical trials for rare bleeding conditions. The IPO is contingent on Nasdaq listing approval, and the company is classified as an emerging growth company with reduced reporting requirements.
2026-02-27 · 0001193125-26-081986
Comparable Deals
2 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 2 using nearest neighbors.
Recent News
Hemab Therapeutics Files for IPO, Signaling Growth in Biopharmaceutical Sector - TradeKaizen
TradeKaizen · 2026-04-11T09:35:12.000Z
Hemab Therapeutics, Clinical-Stage Coagulation Biotech, Files for NASDAQ IPO - TradingView
TradingView · 2026-04-10T20:48:01.000Z
Hemab Therapeutics Holdings Inc - Announces Initial Public Offering Of Common Stock - SEC Filing - TradingView
TradingView · 2026-04-10T20:44:11.000Z